KIR3DL1 and acute myeloid leukemia: Therefore, we conducted the first phase 2 study to determine whether adoptively transferred NK cells from haploidentical and KIR–HLA mismatched donors improve event-free-survival in children with intermediate-risk AML who completed chemotherapy and were in first remission.